-transparent.png){kind=logo}
Alpha 1-proteinase inhibitor (alpha 1-PI) has been prepared as a concentrate in quantities large enough for clinical testing of its safety and efficacy in the treatment of emphysema and other disorders. The alpha 1-PI was purified from Cohn fraction IV-1 paste by polyethylene glycol precipitation and DEAE-Sepharose chromatography. The methods used in the purification are gentle and the resulting product behaves almost identically to the alpha 1-PI from plasma. The protein has been heat treated (60 degrees C, 10 h) to lower the risk of transmission of plasma-borne diseases. This resulted in some aggregation of the protein, but did not cause the generation of new antigenic sites. Half-life studies in animals showed that the protein behaved normally (catabolic t1/2 of 68 h).
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
June 1988,
The American journal of medicine,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
December 1974,
Biochemistry,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
January 1994,
Vox sanguinis,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
March 2010,
P & T : a peer-reviewed journal for formulary management,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
October 1990,
FEBS letters,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
October 1980,
Biochemical and biophysical research communications,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
May 1991,
Biochemistry international,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
July 2001,
Vox sanguinis,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
January 1998,
Journal of postgraduate medicine,
M H Coan, and
W J Brockway, and
H Eguizabal, and
T Krieg, and
M Fournel
November 1989,
Antonie van Leeuwenhoek,
